Lowering the burden of Ebola
In response to the Ebola epidemic in West Africa, a Horizon 2020 EU research initiative ‘EVIDENT’ was launched in November 2014. Equipped with a budget of € 1.7 million, the two-year EVIDENT project provides a research platform which builds upon the success of the European Mobile Laboratory consortium (EMLab) that is performing Ebola Virus Disease (EVD) diagnostics in affected West African countries since March 2014. EVIDENT’s mandate is to scientifically exploit specimens from EVD patients collected as part of the outbreak response in Guinea, Sierra Leone and Nigeria and to gather critical knowledge on B and T cell immunology, biomarkers, virus evolution, virulence determinants, and transmission of Ebola Virus.
News & Events
Professor Stephan Günther of the Bernhard-Nocht-Institute for Tropical Medicine and coordinator in...
With all the experimental data gathered in the field, EVIDENT investigators are trying systems...
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea
Plos Medicine (2016) Mar 1;13(3), doi: 10.1371/journal.pmed.1001967
Cell Death and Disease 2016: (7), doi:10.1038/cddis.2016.55
EVIDENT Fact Sheet
The most important project facts at a glance.Download